Cizzle Bio
About this raise
Cizzle Bio, with a valuation of $70.5 million, is raising funds on Dealmaker Securities. The company is revolutionizing lung cancer detection with its early detection biomarker test. Cizzle Bio’s CIZ1B biomarker test is low-cost, highly accurate, and non-invasive and is a simple blood test for lung cancer detection with 95% sensitivity. The company has a strategic partnership with Bio-Techne to leverage advanced diagnostic tools and scale Cizzle Bio’s technology. William Behnke founded Cizzle Bio in February 2024. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $4.99 million. The campaign proceeds will be used for technology and product development, licensing opportunities, sales and marketing, infrastructure, and general working capital.
Investment Overview
Committed $10,505 :
Deal Terms
Company & Team
Company
- Year Founded
- 2024
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Financials
-
Revenue
-
$0
as of FY2024
- Monthly Burn
-
$70,910
as of Sep '24
-
Runway
-
10 months
as of Sep '24
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $2,500,000
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
04/15/2026 | DealMaker Securities | $70,500,000 | $10,505 | Equity - Common | Active | RegCF |